New hope for ROS1-Positive lung cancer: JYP0322 takes on chemo
Disease control
Not yet recruiting
This Phase 3 trial compares a new drug called JYP0322 with standard platinum-based chemotherapy in 207 people with advanced ROS1-positive non-small cell lung cancer who have already been treated with ROS1-targeted therapy. The main goal is to see if JYP0322 delays cancer growth b…
Phase: PHASE3 • Sponsor: Guangzhou JOYO Pharma Co., Ltd • Aim: Disease control
Last updated Jun 26, 2026 19:19 UTC